APOE, in which the ε4 allele is a strong risk factor for developing late-onset AD [8], has been identified as a novel agonist, as the TREM2–APOE complex can directly modulate AD pathogenesis [68, 69]. This evidence concerns the gene APOE and Alzheimer disease.